...the option to acquire Corus Pharma Inc. ; (B) Cayston sales are reported grouped with Hepsera...

...drug arose (see Clinical Status, B10). Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 840 adefovir dipivoxil...

...a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Hepsera...
...Truvada and Edurant rilpivirine; pulmonary arterial hypertension (PAH) drug Letairis ambrisentan; and HBV drug Hepsera adefovir dipivoxil. WIR...

...rilpivirine, as well as pulmonary arterial hypertension (PAH) drug Letairis ambrisentan and HBV drug Hepsera adefovir dipivoxil...

...Hepsera plus Pegasys peginterferon alfa-2a, 2 patients receiving placebo plus Pegasus, and 0 patients receiving Hepsera...
...at week 72. Data were published in the New England Journal of Medicine. Gilead markets Hepsera...
...Basel, Switzerland) markets Pegasys. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Hepsera adefovir dipivoxil ( GS 840...

...II GS 9310/11 inhaled fosfomycin/ tobramycin CF/chronic obstructive pulmonary disease (COPD) Ph II Liver Hepsera adefovir dipivoxil...

...<400 copies/mL) at week 192 vs. 100% of patients who were switched to Viread from Hepsera...
...Viread previously met the study's primary endpoint of a significant increase in responses compared with Hepsera...
...see BioCentury, June 11, 2007). Gilead markets Viread to treat HIV and HBV infections, and Hepsera...

...<400 copies/mL) at week 192 vs. 99% of patients who were switched to Viread from Hepsera...
...Viread previously met the study's primary endpoint of a significant increase in responses compared with Hepsera...
...see BioCentury, July 2, 2007). Gilead markets Viread to treat HIV and HBV infections, and Hepsera...

...tenofovir to a 2002 deal under which GSK received exclusive rights to Gilead's HBV drug Hepsera...

...of a significantly greater mean reduction from baseline in HBV DNA at week 24 vs. Hepsera...
...16% of Hepsera patients. At 48 weeks, 57% and 20% of patients on Baraclude and Hepsera...
...achieved ALT normalization at 24 and 48 weeks, respectively, compared to 39% and 46% of Hepsera...